Premium
Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin‐producing ability of endothelial cells through interactions with their receptors
Author(s) -
Yamagishi Sho-ichi,
Yamamoto Yasuhiko,
Harada Shin-ichi,
Hsu Cheng-Chin,
Yamamoto Hiroshi
Publication year - 1996
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(96)00279-7
Subject(s) - prostacyclin , angiogenesis , receptor , umbilical vein , microbiology and biotechnology , endothelial stem cell , stimulation , advanced glycation end product , glycosylation , biology , endocrinology , medicine , chemistry , biochemistry , glycation , cancer research , in vitro
The influence of advanced glycosylation end products (AGE) on endothelial cells was investigated. When human umbilical endothelial cells were cultured with AGE‐bovine serum albumin, viable cell number as well as DNA synthesis was significantly stimulated, whereas prostacyclin production by the endothelial cells was decreased. Antisense oligodeoxyribonucleotides against mRNA coding for AGE receptor were found to reverse both the AGE‐induced growth stimulation and the inhibition of prostacyclin production in endothelial cells. These results thus suggest that AGE ligand‐receptor interactions in endothelial cells can promote angiogenesis and thrombogenesis, leading to the development of diabetic vascular complications.